Alexion Pharmaceuticals, Inc.
METHODS FOR TREATMENT OF REFRACTORY GENERALIZED MYASTHENIA GRAVIS

Last updated:

Abstract:

The disclosure provides methods of treating myasthenia gravis (MG) in a subject in need thereof by administering to the subject a substance that specifically binds complement component 5 (C5). In certain embodiments, the substance that specifically binds C5 is a binding protein, such as an anti-C5 antibody.

Status:
Application
Type:

Utility

Filling date:

15 Jan 2021

Issue date:

12 Aug 2021